Company Monitoring Page for AbbVie

latest headlines for company on cafepharma

How Johnson & Johnson Beat Every Other Big Pharma Stock in 2016
Motley Fool
Thu, 01/19/17 - 11:26 am
Tags:
JNJ, pharma stocks, AbbVie, Merck
This Army Vet Is Fighting Hep C With Big Pharma’s Help
Bloomberg
Thu, 12/29/16 - 10:18 am
Tags:
hepatitis C, AbbVie, Merck, Gilead Sciences
3 Biggest Risks for AbbVie in 2017
Motley Fool
Wed, 12/28/16 - 11:03 am
Tags:
AbbVie, Humira, biosimilars, Imbruvica, Viekira Pak, Elagolix, risankizumab
Galapagos, AbbVie glimpse early progress in search of a cystic fibrosis triple to rival Vertex
Endpoints
Wed, 12/21/16 - 11:10 am
Tags:
Galapagos, AbbVie, Vertex Pharmaceuticals, cystic fibrosis, GLPG1837
AbbVie Files for Approval of Hepatitis C Treatment in the US
Yahoo/GuruFocus
Tue, 12/20/16 - 12:20 pm
Tags:
AbbVie, hepatitis C, glecaprevir/pibrentasvir
Gilead's HCV NDA Means Nothing
Seeking Alpha
Sun, 12/11/16 - 11:55 am
Tags:
Gilead Sciences, hepatitis C, SOF/VEL/VOX, Epclusa, AbbVie
Standing Up To The Test Of Time: Two Cancer Drugs That Could Survive A Hobbled FDA
Forbes
Thu, 12/8/16 - 09:59 am
Tags:
FDA, Seattle Genetics, Takeda, Adcetris, Hodgkin's lymphoma, AbbVie, JNJ, Ibruvica, mantle cell lymphoma
AbbVie breast cancer drug falls short in Phase 2
BioPharma Dive
Wed, 12/7/16 - 07:45 pm
Tags:
AbbVie, breast cancer, veliparib, PARP inhibitors, BRCA-mutant breast cancer
AbbVie and Johns Hopkins to Collaborate on Cancer Research
Yahoo
Mon, 12/5/16 - 09:55 am
Tags:
AbbVie, Johns Hopkins, cancer, R&D
As Humira readies for biosimilar rivals, AbbVie looks to ASH to build oncology momentum
Fierce Pharma
Sat, 12/3/16 - 09:21 am
Tags:
Humira, AbbVie, biosimilars, ASH
Elagolix May Become a Leading Uterine Fibroids Drug
Market Realist
Tue, 11/29/16 - 05:35 pm
Tags:
uterine fibroids, Elagolix, AbbVie, Neurocrine Biosciences
AbbVie’s Imbruvica Expected to Become a Leading Oncology Drug
Market Realist
Tue, 11/29/16 - 09:46 am
Tags:
AbbVie, Imbruvica, oncology, CLL
Gilead Takes Lead on Crohn's over AbbVie
Investopedia
Mon, 11/28/16 - 11:33 pm
Tags:
Gilead Sciences, AbbVie, Crohn's Disease, Galapagos, filgotinib, ABT-494
AbbVie Ends Halozyme Development Deal
Investopedia
Tue, 11/22/16 - 09:43 pm
Tags:
AbbVie, Halozyme, tnf-alpha, drug development, drug delivery
Halozyme shares drop after AbbVie punts a failed program; Celgene buys another cancer drug
Endpoints
Mon, 11/21/16 - 11:27 am
Tags:
Halozyme, AbbVie, Celgene, marizomib
What puts a new drug launch in line for victory? Ask Gilead, Biogen and J&J
Fierce Pharma
Thu, 11/17/16 - 10:01 am
Tags:
Gilead Sciences, Biogen, JNJ, drug launches, AbbVie, Sovaldi, Imbruvica, Tecfidera
After The Deluge, Hep C Players Look For Opportunity
Seeking Alpha
Thu, 11/17/16 - 09:57 am
Tags:
hepatitis C, Gilead Sciences, AbbVie, Epclusa, glecaprevir/pibrentasvir, sofosbuvir/velpatasvir
AbbVie's Humira a Step Closer to Approval in Europe
Yahoo/GuruFocus
Wed, 11/16/16 - 09:50 am
Tags:
AbbVie, Humira, Europe
AbbVie's pan-genotypic hep C prospect shines in trials, putting the heat on rival Gilead
Fierce Pharma
Tue, 11/15/16 - 09:36 am
Tags:
AbbVie, hepatitis C, Gilead Sciences, Epclusa
AbbVie reports positive 8-week data in HCV
BioPharma Dive
Mon, 11/14/16 - 12:00 pm
Tags:
AbbVie, hepatitis C, glecaprevir/pibrentasvir

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.